Cel Sci (CVM) Share-based Compensation (2010 - 2026)
Cel Sci (CVM) posted Share-based Compensation of $451381.0 for Q1 2026, up 1.83% sequentially from $443275.0 in Q4 2025, and down 34.17% YoY from $685668.0 in Q1 2025.
Cel Sci (CVM) Share-based Compensation (2010 - 2026) Analysis & Trends
Cel Sci has reported Share-based Compensation for 16 years, with the latest figure at $451381.0 in Q1 2026.
- Quarterly Share-based Compensation fell 34.17% year-over-year to $451381.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $252280.0 (down 88.56% YoY) and the FY2025 annual result came in at $754673.0, down 12.09% from the prior year.
- Share-based Compensation climbed to $451381.0 in Q1 2026 per CVM's latest filing, from $443275.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $5.8 million in Q3 2023 and troughed at -$715818.0 in Q3 2025.
- A 5-year average of $1.3 million and a median of $745993.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation jumped 679.16% in 2023, then sank 995.59% in 2025.
- Over 5 years, Share-based Compensation stood at $1.7 million in 2022, then slipped by 18.78% to $1.4 million in 2023, then plunged by 48.6% to $711381.0 in 2024, then plunged by 37.69% to $443275.0 in 2025, then increased by 1.83% to $451381.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $451381.0, $443275.0, and -$715818.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | 454,094.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 451,381.00 |
| Mar 31, 2026 | 451,381.00 |
| Dec 31, 2025 | 443,275.00 |
| Dec 31, 2025 | 443,275.00 |
| Sep 30, 2025 | -715,818.00 |
| Sep 30, 2025 | -715,818.00 |
| Jun 30, 2025 | 73,442.00 |
| Jun 30, 2025 | 73,442.00 |
| Mar 31, 2025 | 685,668.00 |
| Mar 31, 2025 | 685,668.00 |
| Dec 31, 2024 | 711,381.00 |
| Dec 31, 2024 | 711,381.00 |
| Sep 30, 2024 | 79,927.00 |
| Sep 30, 2024 | 79,927.00 |
| Jun 30, 2024 | 728,120.00 |
| Jun 30, 2024 | 728,120.00 |
| Mar 31, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Dec 31, 2023 | 1.38 Mn |